PE20231942A1 - Formulaciones inyectables de accion prolongada de sales de pamoato de ketamina - Google Patents
Formulaciones inyectables de accion prolongada de sales de pamoato de ketaminaInfo
- Publication number
- PE20231942A1 PE20231942A1 PE2022000484A PE2022000484A PE20231942A1 PE 20231942 A1 PE20231942 A1 PE 20231942A1 PE 2022000484 A PE2022000484 A PE 2022000484A PE 2022000484 A PE2022000484 A PE 2022000484A PE 20231942 A1 PE20231942 A1 PE 20231942A1
- Authority
- PE
- Peru
- Prior art keywords
- ketamine
- pamoate salt
- ketamine pamoate
- salt
- long
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 10
- 229960003299 ketamine Drugs 0.000 title abstract 9
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 title abstract 7
- 239000007972 injectable composition Substances 0.000 title 1
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 abstract 2
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 2
- 238000013268 sustained release Methods 0.000 abstract 2
- 239000012730 sustained-release form Substances 0.000 abstract 2
- 206010002091 Anaesthesia Diseases 0.000 abstract 1
- 230000037005 anaesthesia Effects 0.000 abstract 1
- 230000036592 analgesia Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 239000007900 aqueous suspension Substances 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 229940102223 injectable solution Drugs 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invencion se refiere a una composicion farmaceutica de liberacion sostenida que comprende 1 % p/p a 99% p/p de una forma cristalina o amorfa de una sal de pamoato de ketamina y un portador farmaceuticamente aceptable de la misma, en donde la sal de pamoato de ketamina se selecciona del grupo que consiste en sal de pamoato de R, S-ketamina, sal de pamoato de S-ketamina, sal de pamoato de R-ketamina y cualquier combinacion de los mismos, en donde la sal de pamoato de ketamina tiene una estequiometria de 2:1 o 1:1 de ketamina a pamoato, o una combinacion de los mismos. La forma cristalina de la sal de pamoato de ketamina se representa mediante un patron de difraccion de rayos X en polvo (XRPD) que comprende uno o mas valores de 2-theta seleccionados de 6.0, 10.7, 11.6, 12.0, 13.0, 14.7, 15.0, 22.2, 25.2 y 30.0 (+/- 0.2 2-theta). Las composiciones incluyen suspension acuosa inyectable, solucion inyectable y sistema de administracion de matriz, que pueden proporcionar una liberacion sostenida para anestesia, analgesia o tratamiento del sistema nervioso central y enfermedades antiinflamatorias.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962951061P | 2019-12-20 | 2019-12-20 | |
| PCT/CN2020/137496 WO2021121366A1 (en) | 2019-12-20 | 2020-12-18 | Long-acting injectable formulations of ketamine pamoate salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231942A1 true PE20231942A1 (es) | 2023-12-05 |
Family
ID=76478186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022000484A PE20231942A1 (es) | 2019-12-20 | 2020-12-18 | Formulaciones inyectables de accion prolongada de sales de pamoato de ketamina |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240099994A1 (es) |
| EP (1) | EP4076410A4 (es) |
| JP (1) | JP2023505963A (es) |
| KR (1) | KR20220118427A (es) |
| CN (1) | CN114340603B (es) |
| AR (1) | AR120816A1 (es) |
| AU (1) | AU2020410549A1 (es) |
| BR (1) | BR112022012255A2 (es) |
| CA (1) | CA3152593A1 (es) |
| CL (1) | CL2022001636A1 (es) |
| CO (1) | CO2022003543A2 (es) |
| IL (1) | IL294089A (es) |
| MX (1) | MX2022006596A (es) |
| PE (1) | PE20231942A1 (es) |
| TW (1) | TW202135782A (es) |
| WO (1) | WO2021121366A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2019160057A1 (ja) | 2018-02-15 | 2021-02-04 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
| AU2019262197A1 (en) | 2018-05-04 | 2020-11-26 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| WO2023178039A1 (en) * | 2022-03-14 | 2023-09-21 | Perception Neuroscience, Inc. | Pharmaceutical formulations of r-ketamine |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080293695A1 (en) * | 2007-05-22 | 2008-11-27 | David William Bristol | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance |
| ES2745024T3 (es) * | 2013-03-15 | 2020-02-27 | Janssen Pharmaceutica Nv | Composición farmacéutica de clorhidrato de S-ketamina |
| US20190240184A1 (en) * | 2016-10-27 | 2019-08-08 | National University Corporation Chiba University | Pharmaceutical applications for (s)-norketamine and salts thereof |
| BR112019013192A2 (pt) * | 2016-12-26 | 2019-12-10 | Cellix Bio Private Ltd | composto e composição farmacêutica |
| US10441544B2 (en) * | 2017-10-10 | 2019-10-15 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| AU2018348359C1 (en) * | 2017-10-10 | 2023-10-12 | Douglas Pharmaceuticals Ltd. | Extended release pharmaceutical formulation and methods of treatment |
| WO2019172920A1 (en) * | 2018-03-09 | 2019-09-12 | Rk Pharmaceuticals, Llc | Injectable composition for controlled-release of active ingredient to manage postoperative pain or neuropathic back pain |
| WO2019186357A1 (en) * | 2018-03-26 | 2019-10-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| KR20210116517A (ko) * | 2019-01-11 | 2021-09-27 | 에일러 파마슈티컬스 아이엔씨. | 케타민 파모에이트 및 이의 용도 |
-
2020
- 2020-12-18 AR ARP200103549A patent/AR120816A1/es unknown
- 2020-12-18 AU AU2020410549A patent/AU2020410549A1/en active Pending
- 2020-12-18 TW TW109145042A patent/TW202135782A/zh unknown
- 2020-12-18 EP EP20901388.7A patent/EP4076410A4/en active Pending
- 2020-12-18 PE PE2022000484A patent/PE20231942A1/es unknown
- 2020-12-18 JP JP2022531055A patent/JP2023505963A/ja active Pending
- 2020-12-18 MX MX2022006596A patent/MX2022006596A/es unknown
- 2020-12-18 CN CN202080061800.8A patent/CN114340603B/zh active Active
- 2020-12-18 BR BR112022012255A patent/BR112022012255A2/pt unknown
- 2020-12-18 IL IL294089A patent/IL294089A/en unknown
- 2020-12-18 WO PCT/CN2020/137496 patent/WO2021121366A1/en active Application Filing
- 2020-12-18 CA CA3152593A patent/CA3152593A1/en active Pending
- 2020-12-18 KR KR1020227020779A patent/KR20220118427A/ko active Search and Examination
- 2020-12-18 US US17/754,738 patent/US20240099994A1/en active Pending
-
2022
- 2022-03-25 CO CONC2022/0003543A patent/CO2022003543A2/es unknown
- 2022-06-16 CL CL2022001636A patent/CL2022001636A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240099994A1 (en) | 2024-03-28 |
| AR120816A1 (es) | 2022-03-23 |
| MX2022006596A (es) | 2022-07-05 |
| TW202135782A (zh) | 2021-10-01 |
| CN114340603B (zh) | 2024-06-07 |
| AU2020410549A1 (en) | 2022-04-14 |
| WO2021121366A1 (en) | 2021-06-24 |
| BR112022012255A2 (pt) | 2022-08-30 |
| KR20220118427A (ko) | 2022-08-25 |
| EP4076410A1 (en) | 2022-10-26 |
| JP2023505963A (ja) | 2023-02-14 |
| CL2022001636A1 (es) | 2023-01-27 |
| CA3152593A1 (en) | 2021-06-24 |
| CN114340603A (zh) | 2022-04-12 |
| CO2022003543A2 (es) | 2022-04-19 |
| IL294089A (en) | 2022-08-01 |
| EP4076410A4 (en) | 2024-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231942A1 (es) | Formulaciones inyectables de accion prolongada de sales de pamoato de ketamina | |
| ES2669793T3 (es) | Derivados de 2-quinolinil-ácido acético como compuestos antivirales del VIH | |
| ES2668422T3 (es) | Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH | |
| PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
| UY30411A1 (es) | Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
| UY37007A (es) | Compuestos derivados de purinas, estimuladores de genes de interferón | |
| EA201992601A1 (ru) | Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak | |
| ES2541689T3 (es) | Métodos para tratar trastornos resistentes a metotrexato con 10-propargil-2-desazaaminopterina | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| CO6670589A2 (es) | Compuestos para reducir la producción de beta-amiloide | |
| CL2020001343A1 (es) | Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson. | |
| PA8547701A1 (es) | Nucleosidos 4 substituidos. | |
| CU20200053A7 (es) | Compuesto de pirimidina como inhibidor de las janocinasas, composición, forma cristalina y proceso de preparación | |
| AR116116A1 (es) | Proceso para elaborar inhibidores de jak e intermediarios de los mismos | |
| BR112015023705A2 (pt) | composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia) | |
| AR044856A1 (es) | Acidos biariloximetilarenocarboxilicos; procedimientos para su preparacion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos. | |
| JP2019532067A5 (es) | ||
| BR0309990A (pt) | Processo para produzir um hidrato de um sal de adição de ácido de um composto, hidrato de um sal de adição de ácido de um composto, composição farmacêutica ou veterinária, uso de um hidrato agente para o uso como um inibidor ou p-glicoproteìna, e, métodos para modular a mdr modulada pela p-gp no tratamento de tumores, para potencializar a citotoxicidade de um agente citotóxico para uma célula de tumor, para tratar uma doença em que o patógeno responsável exibe resistência a múltiplos medicamentos, e para realçar uma caracterìstica de um agente terapêutico | |
| CO2021014210A2 (es) | Compuestos de pirrol | |
| CO2024001367A2 (es) | Compuestos antivirales | |
| NI202100012A (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| PE20230601A1 (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
| EA201000120A1 (ru) | Фармацевтические композиции, содержащие холиновые соли янтарной кислоты, для интраназального введения | |
| ECSP045373A (es) | Sales de tolterodina | |
| PE20160284A1 (es) | Derivados de amida como antogonistas del receptor de acido lisofosfatidico |